Metabolic dysfunction–associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide. Despite its high global prevalence, NAFLD is often under-recognized due to the absence of reliable noninvasive biomarkers for diagnosis and staging. Growing evidence suggests that the gut microbiome plays a significant role in the occurrence and progression of NAFLD by causing immune dysregulation and metabolic alterations due to gut dysbiosis. The rapid advancement of sequencing tools and metabolomics has enabled the identification of alterations in microbiome signatures and gut microbiota-derived metabolite profiles in numerous clinical studies related to NAFLD. Overall, these studies have shown a decrease in α-diversity and changes in gut microbiota abundance, characterized by increased levels of Escherichia and Prevotella, and decreased levels of Akkermansia muciniphila and Faecalibacterium in patients with NAFLD. Furthermore, bile acids, short-chain fatty acids, trimethylamine N-oxide, and tryptophan metabolites are believed to be closely associated with the onset and progression of NAFLD. In this review, we provide novel insights into the vital role of gut microbiome in the pathogenesis of NAFLD. Specifically, we summarize the major classes of gut microbiota and metabolic biomarkers in NAFLD, thereby highlighting the links between specific bacterial species and certain gut microbiota-derived metabolites in patients with NAFLD.
Systemic lupus erythematosus (SLE) presents diagnostic and disease monitoring challenges due to its heterogeneity and variable activity. In this cross-sectional study, we investigated the association of plasma catecholamine (CA) metabolites with SLE status and disease activity. Plasma samples from 88 SLE patients and 64 healthy controls were analyzed using targeted liquid chromatography-tandem mass spectrometry to quantify dopamine (DA), epinephrine (E), norepinephrine (NE), 3-methoxytyramine (3MT), metanephrine (MN), and normetanephrine (NMN). Significant alterations in CA metabolites levels were observed in SLE patients compared to controls, independent of glucocorticoid treatment. Orthogonal partial least squares-discriminant analysis (OPLS-DA) suggested distinct metabolic profiles in active SLE. NE, NMN, MN, and E showed notable group differences and correlations with inflammatory markers, clinical features, complement levels, and SLE Disease Activity Index (SLEDAI) scores. Receiver operating characteristic analysis demonstrated strong diagnostic performance for individual CA biomarkers, while combined plasma CA metabolites assessment yielded superior predictive capability for SLE activity (AUC: 0.866, 95% CI: 0.785–0.947). These findings highlight the potential of plasma CA metabolites, particularly NE and NMN, are associated with SLE disease activity and may serve as potential associative biomarkers. Further validation in independent and longitudinal cohorts is warranted.
Osteoarthritis (OA) is an age-related condition affecting the entire joint. Abnormal lipid regulation may act as a trigger for disease onset, or result from inflammation or mechanical injury; alternatively, it may merely manifest as a detectable signal without any direct mechanistic significance. Given that causality cannot be determined based on abundance alone, we propose a compartment-cell temporal framework: pathogenic effects may arise when lipid composition, flux or localisation exceed the tissue’s adaptive capacity. Experimental evidence plays a causal role for certain cholesterol and fatty acid pathways, whilst human lipid research remains at the stage of exploring associations. Lipid stress, through dysregulation of organelles such as the endoplasmic reticulum and mitochondria, converges with common features of joint ageing—including cellular senescence, mitochondrial dysfunction, imbalances in autophagy and proteostasis, inflammation, and alterations in signalling—and may reconcile previous conflicting findings in areas such as apolipoprotein E and fatty acid oxidation. At the translational level, weight loss and metabolic management are feasible short-term strategies, and the prospects for lipid stratification are promising; however, testing has not yet met clinical diagnostic standards, and lipid nanoparticles have not yet been established as a therapeutic method. At present, they should be regarded as delivery vehicles; challenges such as joint preservation, deep tissue delivery, and safety still need to be overcome, and validation in human tissue is required. In summary, lipid research contributes to the classification and treatment of OA, but a strict distinction must be made between the maturity of causal evidence and mere correlation.